Sun Pharmaceutical Industries Limited

Ranbaxy Laboratories, Inc.

Romi Barat Singh

Satish Kumar Jain

Anuj Kumar Fanda

Kalaiselvan Ramaraju

Rajesh Srikrishan Shear

Shavej Ahmad

Ashish Kumar

Ravish Sharma

Pulak Kumar Metia

Pruthvipathy Katikaneni

Balaram Mondal

Paras P Jain

Prabhakar Konatham

Swarna Pappu

Ravinder Singh

Varinder Kumar

Dileep Jami

Harinder Singh

Sandeep Kumar Vats

Rajesh Rao

Ajay Kumar Singla

Kumaravel Vivek

Suchitra Kaushik

Sumit Madan

Ravindra Agarwal

Vishnubhotla Nagaprasad

Bhupesh Kumar Mittal

Amit Kumar

Rajiv Malik

Sunilendu Bhushan Roy

Rahul Bhargava

Lalit Kumar Khurana

Pannanchukunnath Manoj Kumar

Mohit Mittal

Rajan Kumar Verma

Kanwarpreet Singh Bakshi

Umesh Vinayakrao Barabde

Sreekanth Narravula

Murali Krishna Bhavarisetti

Balaran Mondal

Rajan K Verma

The present invention relates to an extended release multiparticulate composition comprising a plurality of discrete units, each discrete unit comprising ranolazine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The said multiparticulate composition is sprinkled onto soft foods or liquids for oral administration. Further, the multiparticulate composition is bioequivalent to the marketed extended release tablet. It further relates to a process of preparation of said multiparticulate composition and method of treatment of patients suffering from angina by administering said composition.

Extended release multiparticulates of ranolazine

The present invention discloses an extended release multi-particulate sprinkle composition comprising a plurality of discrete units, each discrete unit comprising quetiapine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

Multi-particulate pharmaceutical composition of quetiapine

The present invention relates to extended release liquid compositions of metformin. The extended release liquid compositions are in the form of suspensions or reconstituted powder for suspensions. Said extended release liquid compositions comprise cores of metformin coated with a release-controlling agent, wherein the coated cores are dispersed in a suspension base. Said extended release liquid compositions provide the desired uniform extended release profile throughout the shelf-life of the composition. Furthermore, said extended release liquid compositions are bioequivalent to a reference composition. It also relates to processes for the preparation of said extended release liquid compositions.

Extended release liquid compositions of metformin

The present invention relates to extended release liquid compositions of guanfacine. The extended release liquid compositions of the present invention are bioequivalent to marketed extended release tablet compositions of guanfacine. Said extended release liquid compositions provide substantially similar in-vitro dissolution release profile upon storage for at least seven days. Further, the extended release liquid compositions are stable. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions.

Extended release liquid compositions of guanfacine

The present invention relates to a dual-chamber pack with a first chamber comprising a container; and a second chamber comprising a reservoir, a biphasic connector, a plunger, and a plug with a breakable polymeric membrane. The container of the first chamber is prefilled with a pharmaceutically acceptable vehicle and the reservoir of the second chamber is prefilled with a solid composition of an active ingredient, wherein the solid composition of the active ingredient is mixed with the pharmaceutically acceptable vehicle to form a liquid pharmaceutical composition upon activation of the dual-chamber pack.

Drug delivery device for pharmaceutical compositions

The present invention relates to novel gastroretentive dosage systems, in particular, a floating capsule which releases the drug without any lag time and which remains buoyant for a sufficient period of time in the stomach. Further, the invention relates to the process of preparation thereof.

Gastroretentive dosage system and process of preparation thereof

An oral pharmaceutical composition of isotretinoin and a carrier substrate, having isotretinoin in the form of gel, dispersion, solution or emulsion, which is absorbed onto the carrier substrate to form solid particles, powder, or granules. The oral pharmaceutical composition has enhanced bioavailability. A process is used for preparing the oral composition.

Oral pharmaceutical composition of isotretinoin

The present invention relates to a method for preparing a stable extended release suspension composition comprising multiple coated cores of an active ingredient by using a suspension base, wherein the suspension base ensures substantially similar in-vitro dissolution release profile of the active ingredient upon storage of the suspension compositions for at least seven days.

Extended release suspension compositions

The present invention relates to oral liquid compositions of guanfacine. The liquid compositions can be immediate release or extended release compositions. The compositions comprise guanfacine in a concentration from about 0.1 mg/mL to about 12.0 mg/mL of the composition. The liquid compositions can be in the form of ready-to use liquid compositions or reconstituted liquid compositions. It further relates to processes for the preparation of said oral liquid compositions.

Oral liquid compositions of guanfacine

The present invention relates to an osmotic floating tablet comprising: (i) an inner core comprising a drug, one or more low density polymers, and one or more pharmaceutically acceptable excipients; and (ii) an outer osmotic coating surrounding the inner core that is substantially permeable to surrounding fluids and substantially impermeable to the drug. The present invention also relates to processes for the preparation of said tablets.

Osmotic floating tablets

The present invention relates to controlled-release pharmaceutical dosage forms comprising a solid dispersion of a poorly water-soluble or insoluble drug with improved solubility and thus improved dissolution in an aqueous medium. The invention further discloses a process of preparation of these controlled-release dosage forms.

Dissolution enhanced controlled drug delivery system for poorly water soluble drugs

This disclosure provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units, wherein said capsule dosage form is bioequivalent to the marketed Toprol-XL&#xae; tablet. The extended-release capsule dosage form comprising coated discrete units can be sprinkled onto food to ease administration to patients who have difficulty swallowing tablets or capsules.

Capsule dosage form of metoprolol succinate

Growing community of inventors

Varanasi, India

Romi Barat Singh